Program
Tamoxifen
Also written as “tamoxifen”, “Tamoxifen (Nolvadex)” and “TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen”.
Its studies are mostly in Breast Neoplasms · Neoplasms · Ovarian Neoplasms, led by 6 companies.
Drug pageTamoxifen: every studyMany companies study it; this page follows only the 14 they lead. All 207 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 80 open or running | phase 3since Sep 30, 2005 | Sep 30, 2005 | none ahead |
| Pfizer | 20 open or running | phase 4since Aug 25, 2010 | May 8, 2002 | none ahead |
| Changchun GeneScience Pharmaceuticalits history only | 11 open or running | phase 3since May 31, 2024 | May 31, 2024 | none ahead |
| Daré Bioscienceits history only | 10 open or running | phase 2since May 2, 2022 | May 2, 2022 | none ahead |
| Mediclinic Middle Eastits history only | 10 open or running | phase 2since Mar 14, 2019 | Mar 14, 2019 | none ahead |
| Nalagenetics Pteits history only | 10 open or running | no phasesince Aug 12, 2022 | Aug 12, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pfizer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 8, 2002First study: phase 3 study in Breast NeoplasmsFirst studyNCT00036270 · 9,779 enrolled · United States
- Aug 25, 2010Phase 4 study in PharmacokineticsNCT01189500 · 30 enrolled · United States
TargetBeta
“Estrogen receptor alpha modulator”ChEMBL 37, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
All 2 Pfizer leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01189500Pharmacokinetics · United States | 4 | Completed | Oct 2010 | 30 |
| NCT00036270Breast Neoplasms · United States | 3 | Completed | Oct 2008 | 9,779 |
How it is read
Names in the registry
- “Tamoxifen”, 11 entries
- “tamoxifen”, 2 entries
- “Tamoxifen (Nolvadex)”, 2 entries
- “TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen”, 1 entry
- “T Leuprolide Injectable Emulsion”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 14 studies
- Neoplasms, 2 studies
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.